Sectorally, selling was seen in realty, public sector, metal, oil & gas, and energy space while some buying was seen in healthcare. Sharp selloff was also seen in the small & midcap spaces, which plunged nearly 3% each.
After an inspection at the Pithampur plant, the USFDA issued a warning letter stating that the company s methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to good manufacturing practices, and that its drug products are adulterated.
Cipla s India business that contributes 42% to overall revenue grew 10% YoY to Rs 2817 crore in Q2FY24 with continued momentum across branded prescription, trade generics and consumer health verticals